The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,597,379 in first-year total cost, median $962,425.
Most frequent study sections
- Special Emphasis Panel[ZAA1 DD (44)]2
- Special Emphasis Panel[ZAA1 DD (06)]1
- Special Emphasis Panel[ZAA1 EE (02)]1
Most frequent institutions
- CERECOR. INC.1
- LOHOCLA RESEARCH CORPORATION1
- NAPROGENIX, INC1
- THERALY FIBROSIS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Development of a TRAIL-based therapy for alcohol related chronic pancreatitis1U44AA026111-01 | ROSCHKE, VICTOR V | THERALY FIBROSIS, INC., MD | $924,849 | ZAA1 |
| 2017 | Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence1U44AA026126-01 | LITTLETON, JOHN M. | NAPROGENIX, INC, KY | $672,530 | ZAA1 |
| 2016 | Early Stage Development of a Selective Kappa Opioid Receptor (KOR) Antagonist to Treat Alcohol Use Disorder1U44AA025253-01 | MARCUS, RONALD N | CERECOR. INC., MD | $1,000,000 | ZAA1 |
| 2015 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder1U44AA024905-01 | TABAKOFF, BORIS | LOHOCLA RESEARCH CORPORATION, CO | $1,000,000 | ZAA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.